Taysha Gene Therapies, Inc.

The momentum for this stock is not very good. Taysha Gene Therapies, Inc. is not a good value stock. Taysha Gene Therapies, Inc. is a mediocre stock to choose.

News

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies...\n more…

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by Brokerages

Zolmax Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the stock, Marketbeat reports...\n more…

Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $6.22

Zolmax Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been given a consensus rating of "Buy" by the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Nine...\n more…

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

Ticker Report Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given an average rating of "Buy" by the nine brokerages that are presently covering the company, Marketbeat reports...\n more…

FY2024 EPS Estimates for Taysha Gene Therapies, Inc. Boosted by Analyst (NASDAQ:TSHA)

Zolmax Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Analysts at Chardan Capital boosted their FY2024 EPS estimates for Taysha Gene Therapies in a research note issued to investors on...\n more…